CDK6 and acute myeloid leukemia: Specifically, we tested a von Hippel–Lindau (VHL)-based PROTAC named CST651 and two cereblon (CRBN)-based PROTACs, named GU3341 and BSJ-03-123 [23] (Figure 1A), and with the latter already shown to cause a robust anti-proliferative effect in CDK6-dependent AML cell lines [21].